Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer (clinicaltrials.gov) - Oct 28, 2026 - P=N/A | N=456 | Not yet recruiting | Sponsor: Henan Cancer Hospital | Initiation date: Aug 2026 ➔ Nov 2026
Trial initiation date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR
|